Crossmark

Empagliflozin and dapagliflozin decreased atrial monoamine oxidase expression and alleviated oxidative stress in overweight non-diabetic cardiac patients

Crossref DOI link: https://doi.org/10.1007/s11010-024-05076-z

Published Online: 2024-07-23

Published Print: 2025-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ionică, Loredana N.

Buriman, Darius G.

Lința, Adina V.

Șoșdean, Raluca

Lascu, Ana

Streian, Caius G.

Feier, Horea B.

Petrescu, Lucian

Mozoș, Ioana M.

Sturza, Adrian

Muntean, Danina M.
License Information

Text and Data Mining valid from 2024-07-23

Version of Record valid from 2024-07-23
More Information

Article History

Received: 24 May 2024

Accepted: 16 July 2024

First Online: 23 July 2024

Declarations

:

: The authors declare no conflict of interest.

: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Commission for Research Ethics of “Victor Babeș” University of Medicine and Pharmacy of Timisoara, Romania (No. 05/10.02.2023).

: Informed consent was obtained from all the patients involved in the study.

Document is current

Any future updates will be listed below